GLP Watchdog

Eden vs Gala

Eden has an open FDA warning letter dated June 8, 2026. Gala has none. On compounded semaglutide injection, Eden costs $960 less a year at standing rates: $99 a month against $179 a month at Gala. It is one of two products the two sell at comparable terms.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Eden / Gala

Eden logo

Eden

8.7/10

Gala logo

Gala

8.5/10

FDA warning letters
None on record
Pharmacy
None named in our record
None named in our record
Lowest standing price
$99/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit Eden
Visit Gala

Both Eden and Gala are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (Eden 8.7, Gala 8.5). How we are paid

What the record shows

  1. 01

    Eden has an open FDA warning letter dated June 8, 2026. Gala has none.

  2. 02

    Neither names the pharmacy that compounds its medication.

  3. 03

    On compounded semaglutide injection, Eden costs $960 less a year at standing rates: $99 a month against $179 a month at Gala. It is one of two products the two sell at comparable terms.

  4. 04

    Only Gala lists a price for brand-name semaglutide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Eden

Gala

Compounded semaglutide injection

$99/moLower

$1,188 a year

$179/mo

$2,148 a year

Compounded tirzepatide injection

$129/moLower

$1,548 a year

$179/mo

$2,148 a year

Brand-name semaglutide pen
Not sold or not priced

$1,299/mo

$15,588 a year

Price includes
Medication, clinician visits, shipping, coaching
Medication, clinician visits, shipping
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
Yearly plan for the $179 rate; 72 hours' notice before the billing date to cancel
Refunds
No refunds once an order is fulfilled
No refund on cancellation; full refund only if the medical provider disqualifies you
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. Eden: October 30, 2026. Gala: October 17, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Eden

8.7/10
  • $960 a year less on compounded semaglutide injection
  • $600 a year less on compounded tirzepatide injection
  • Open FDA warning letter, June 8, 2026
  • Names no compounding pharmacy
Visit Eden

The case for Gala

8.5/10
  • No FDA warning letter on record
  • Sells brand-name semaglutide pen, which Eden does not price
  • Names no compounding pharmacy
Visit Gala

Scores

Eden 8.7 · Gala 8.5 out of 10. Six weighted parts.

Value25%

10.0A
vs
B
7.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

4.5A
vs
B
7.5

Accessibility10%

10.0A
vs
B
10.0

Support10%

8.5A
vs
B
7.0

The score is the same formula for every seller. Payment does not enter it. Method

Eden vs Gala: questions

Eden has an open FDA warning letter dated June 8, 2026. Gala has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Neither names the pharmacy that compounds its medication.
Eden, by $960 a year at standing rates. Eden: $99 a month, about $1,188 a year. Gala: $179 a month, about $2,148 a year.
Eden states you can cancel at any time; refunds: no refunds once an order is fulfilled. Gala states you can cancel at any time; refunds: no refund on cancellation; full refund only if the medical provider disqualifies you.
Both Eden and Gala are affiliate partners: we are paid if you sign up through our links. Neither is featured. Scores are computed the same way for both (Eden 8.7, Gala 8.5).

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks